Dataset from A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC).

This is a randomized, open-label, multi-center, global, Phase III study to determine the
efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based
SoC chemotherapy in the first-line treatment of patients with epidermal growth factor
receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic NSCLC.